Galapagos NV Gets Notification from EcoR1 Capital LLC
Mechelen, Belgium; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) has received an important transparency notification from EcoR1 Capital LLC, marking a significant point for the company.
Details of the Notification
On September 13, Galapagos learned that Mr. Oleg Nodelman and EcoR1 Capital LLC hold a total of 6,713,553 voting rights in Galapagos. This total includes 839,388 ordinary shares and 5,874,165 American Depository Receipts (ADRs). The notification highlights that these voting rights were obtained by purchasing securities recognized as voting rights.
Breakdown of Holdings
EcoR1 Capital LLC, led by Mr. Oleg Nodelman, oversees investment funds, including EcoR1 Capital Fund Qualified LP and EcoR1 Capital Fund LP. Together, these funds control 10.19% of Galapagos’ voting rights, which recently crossed the crucial 10% mark due to acquisitions made on September 10, 2024. This acquisition underscores a growing interest and investment in Galapagos.
Insight into EcoR1 Capital LLC
EcoR1 Capital LLC functions as a discretionary investment advisory firm, managing investments for clients like individuals, endowments, and foundations. The notification indicates that EcoR1's clients benefit from the associated voting rights, thus enhancing the firm's influence over decisions made within the company. EcoR1 exercises these voting rights at its discretion, without specific instructions from their clients.
Understanding the Importance of Transparency Notifications
Grasping what transparency notifications entail is vital for both shareholders and analysts. These notifications uphold a level of accountability among large shareholders in publicly traded companies. Being aware of significant shifts in voting control can empower investors to make informed decisions while boosting confidence in the company's governance systems.
A Closer Look at Galapagos NV
Galapagos is a biotechnology company focused on creating transformative medicines to tackle chronic health issues. Operating mainly in Europe and the U.S., the firm centers on addressing unmet medical needs, particularly in oncology and immunology. They are committed to merging cutting-edge science with advanced technology and collaborative approaches to develop an impressive range of small molecules and cell therapies.
Commitment to Patient Care
Galapagos is proud of its patient-centered philosophy, ensuring that their therapies are not just innovative but also significantly enhance patients' quality of life. Their commitment goes beyond merely prolonging life; they strive to improve overall well-being. This patient-first approach positions them as pioneers within the biotechnology field.
Contact Information
For media inquiries, Galapagos encourages interested parties to contact:
Marieke Vermeersch
+32 479 490 603
media@glpg.com
Jennifer Wilson
+44 7444 896759
media@glpg.com
For investor inquiries, reach out to:
Sofie Van Gijsel
+1 781 296 1143
ir@glpg.com
Sandra Cauwenberghs
+32 495 584 663
ir@glpg.com
Frequently Asked Questions
What is a transparency notification?
A transparency notification is an official message that informs a company about significant changes in shareholdings or voting rights by major shareholders.
Who is EcoR1 Capital LLC?
EcoR1 Capital LLC is an investment advisory firm controlled by Mr. Oleg Nodelman, overseeing funds that hold significant voting rights in Galapagos NV.
What does it mean to cross the 10% threshold?
Crossing the 10% threshold signifies substantial voting control and can greatly influence decision-making within the company.
How does Galapagos NV impact patient care?
Galapagos NV is dedicated to creating transformative therapies that enhance quality of life and address serious health conditions, especially in oncology and immunology.
How can I contact Galapagos NV for more information?
You can reach out to them regarding media or investor inquiries through the contact details listed above, including phone numbers and email addresses.
